Literature DB >> 16149047

Nutritional therapy improves function and complements corticosteroid intervention in mdx mice.

Eric T Payne1, Nobuo Yasuda, Jacqueline M Bourgeois, Michaela C Devries, M Christine Rodriguez, Junaid Yousuf, Mark A Tarnopolsky.   

Abstract

Corticosteroid therapy for Duchenne muscular dystrophy is effective but associated with long-term side effects. To determine the potential therapeutic benefit from four nutritional compounds (creatine monohydrate, conjugated linoleic acid, alpha-lipoic acid, and beta-hydroxy-beta-methylbutyrate) alone, in combination, and with corticosteroids (prednisolone), we evaluated the effects on several variables in exercising mdx mice. Outcome measures included grip strength, rotarod performance, serum creatine kinase levels, muscle metabolites, internalized myonuclei, and retroperitoneal fat pad weight. In isolation, each nutritional treatment showed some benefit, with the combination therapy showing the most consistent benefits. Prednisolone and the combination therapy together provided the most consistent evidence of efficacy; increased peak grip strength (P < 0.05), decreased grip strength fatigue (P < 0.05), decreased number of internalized myonuclei (P < 0.01), and smaller retroperitoneal fat pad stores (P < 0.001). This study provided evidence for therapeutic benefit from a four-compound combination therapy alone, and in conjunction with corticosteroids in the mdx model of DMD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16149047     DOI: 10.1002/mus.20436

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  24 in total

Review 1.  What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?

Authors:  Jennifer Manning; Dervla O'Malley
Journal:  J Muscle Res Cell Motil       Date:  2015-02-11       Impact factor: 2.698

2.  Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.

Authors:  Ingrid E C Verhaart; Hans Heemskerk; Tatyana G Karnaoukh; Ingrid G M Kolfschoten; Anne Vroon; Gert-Jan B van Ommen; Judith C T van Deutekom; Annemieke Aartsma-Rus
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

Review 3.  High-content drug screening with engineered musculoskeletal tissues.

Authors:  Herman Vandenburgh
Journal:  Tissue Eng Part B Rev       Date:  2010-02       Impact factor: 6.389

4.  VIP-expressing dendritic cells protect against spontaneous autoimmune peripheral polyneuropathy.

Authors:  Mehmet E Yalvac; William David Arnold; Syed-Rehan A Hussain; Cilwyn Braganza; Kimberly M Shontz; Kelly Reed Clark; Christopher M Walker; Eroboghene E Ubogu; Jerry R Mendell; Zarife Sahenk
Journal:  Mol Ther       Date:  2014-04-25       Impact factor: 11.454

5.  Genetic deletion of trkB.T1 increases neuromuscular function.

Authors:  Susan G Dorsey; Richard M Lovering; Cynthia L Renn; Carmen C Leitch; Xinyue Liu; Luke J Tallon; Lisa DeShong Sadzewicz; Abhishek Pratap; Sandra Ott; Naomi Sengamalay; Kristie M Jones; Colleen Barrick; Gianluca Fulgenzi; Jodi Becker; Kevin Voelker; Robert Talmadge; Brandon K Harvey; Ryan M Wyatt; Elizabeth Vernon-Pitts; Chao Zhang; Kevan Shokat; Claire Fraser-Liggett; Rita J Balice-Gordon; Lino Tessarollo; Christopher W Ward
Journal:  Am J Physiol Cell Physiol       Date:  2011-10-05       Impact factor: 4.249

6.  β-Hydroxy-β-methylbutyrate (HMB) prevents dexamethasone-induced myotube atrophy.

Authors:  Zaira Aversa; Nima Alamdari; Estibaliz Castillero; Maurizio Muscaritoli; Filippo Rossi Fanelli; Per-Olof Hasselgren
Journal:  Biochem Biophys Res Commun       Date:  2012-06-13       Impact factor: 3.575

7.  Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial.

Authors:  Elise Mok; Guy Letellier; Jean-Marie Cuisset; André Denjean; Frédéric Gottrand; Corinne Alberti; Régis Hankard
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

8.  Effects of prednisolone on skeletal muscle contractility in mdx mice.

Authors:  Kristen A Baltgalvis; Jarrod A Call; Jason B Nikas; Dawn A Lowe
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

9.  Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures.

Authors:  Christopher F Spurney; Heather Gordish-Dressman; Alfredo D Guerron; Arpana Sali; Gouri S Pandey; Rashmi Rawat; Jack H Van Der Meulen; Hee-Jae Cha; Emidio E Pistilli; Terence A Partridge; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  Muscle Nerve       Date:  2009-05       Impact factor: 3.217

Review 10.  Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Miranda D Grounds; Hannah G Radley; Gordon S Lynch; Kanneboyina Nagaraju; Annamaria De Luca
Journal:  Neurobiol Dis       Date:  2008-04-09       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.